*Correspondence: Roberta Poli, [email protected] These authors have contributed equally to this work and share first authorship This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
doi:10.2147/JMDH.S419245 Karagiannis T, Tsapas A, Athanasiadou E, et al
Our calculator works with any ratio you choose
Its stability, lower cost, and extensive safety record make it the practical default choice
Investing in a machine like this, with its multiple uses, truly feels like an investment in a long lifespan of better health and elite personal performance
Semaglutide users in the STEP 1 trial lost an average of 14.9% of their body weight over 68 weeks